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A myosin-Va tail fragment sequesters dynein light
chains leading to apoptosis in melanoma cells
TC Izidoro-Toledo1,8, AC Borges1,8, DD Araújo1,2,3, DPS Leitão Mazzi1, FO Nascimento Júnior1, JF Sousa1,4, CP Alves1, APB Paiva1,
DM Trindade1,5, EV Patussi1,6, PM Peixoto7, KW Kinnally7 and EM Espreafico*,1
Previous studies proposed that myosin-Va regulates apoptosis by sequestering pro-apoptotic Bmf to the actin cytoskeleton
through dynein light chain-2 (DLC2). Adhesion loss or other cytoskeletal perturbations would unleash Bmf, allowing it to bind
and inhibit pro-survival Bcl2 proteins. Here, we demonstrated that overexpression of a myosin-Va medial tail fragment (MVaf)
harboring the binding site for DLC2 dramatically decreased melanoma cell viability. Morphological and molecular changes,
including surface blebbing, mitochondrial outer membrane permeabilization, cytochrome-c and Smac release, as well as
caspase-9/-3 activation and DNA fragmentation indicated that melanoma cells died of apoptosis. Immobilized MVaf interacted
directly with DLCs, but complexed MVaf/DLCs did not interact with Bmf. Overexpression of DLC2 attenuated MVaf-induced
apoptosis. Thus, we suggest that, MVaf induces apoptosis by sequestering DLC2 and DLC1, thereby unleashing the pair of
sensitizer and activator BH3-only proteins Bmf and Bim. Murine embryonic fibroblasts (MEFs) lacking Bim and Bmf or Bax and
Bak were less sensitive to apoptosis caused by MVaf expression than wild-type MEFs, strengthening the putative role of the
intrinsic apoptotic pathway in this response. Finally, MVaf expression attenuated B16-F10 solid tumor growth in mice,
suggesting that this peptide may be useful as an apoptosis-inducing tool for basic and translational studies.
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Apoptosis is an active process of cell death essential for
embryogenesis, tissue homeostasis, and elimination of
damaged cells in multicellular organisms. Abnormalities in
this process can initiate or contribute to the development of
several diseases, such as autoimmune diseases, neurode-
generative disorders and cancer.1 The Bcl2 family of proteins
constitutes a critical checkpoint in the apoptotic cascade.
Cancer cells frequently express altered ratios of anti- to pro-
apoptotic Bcl2 family members, which promote survival and
confer resistance to therapy.2 The vertebrate dynein light
chains (DLC) 1 and 2 (encoded by DYNLL1 and DYNLL2
genes) are B10 kDa homodimeric hub proteins that interact
with a large number of proteins involved in diverse biological
functions, including the Bcl2 pro-apoptotic proteins Bim and
Bmf, as well as their respective molecular motor partners
dynein and myosin-Va.3,4,5 Myosin-Va is an actin-based
molecular motor, member of the class V myosins, which are
comprised of highly related multi-domain proteins, encoded
by three paralogous genes (MYO5A, MYO5B and MYO5C) in
vertebrates.6 Myosin-Va is ubiquitously involved in the
transport or tethering of a diverse array of cellular components
to the actin cytoskeleton.7,8,9 Interestingly, myosin-Va has
been suggested as a Bmf scavenger that releases the pro-
apoptotic protein upon actin depolymerization or disruption of
cell adhesion,10,12 in analogy with the mechanism proposed
for the regulation of Bim by dynein and DLC1 in a manner
dependent on microtubule integrity.11 Apoptosis triggered by
loss of cell attachment constitutes a physiological form of cell
death known as anoikis, which has a central role in controlling
tissue homeostasis, and is believed to function as a major
barrier against cancer.12,13,14 Therefore, the findings by
Puthalakath et al.10 shed some light into how injuries that
disrupt the actin cytoskeleton trigger cell death, and open
many new questions, such as how these interactions are
regulated, what are their roles in different cellular contexts,
and how do malignant cells display resistance to anoikis. In
the present work, we disrupted myosin-V/DLC2 interactions
by overexpressing fragments derived from the medial tail
region of myosin-Va. Surprisingly, some of the fragments
worked as potent inducers of apoptosis in melanoma cells.
These data provide further evidence of the role of myosin-Va
and DLCs as critical pro-survival molecules.
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Results
Myosin-Va medial tail fragment impairs melanoma cell
viability in an exon-B-dependent manner. To determine
the impact of DLC2-myosin-Va interaction in melanoma cell
viability, the effects of expressing myosin-Va fragments
(MVaf), which include the DLC2-binding domain,5,15 were
determined. Of three fragments generated, two contain exon
B (MVaf1 and MVaf2) and one does not (MVaf3). A myosin-
Vc fragment (MVcf) of a region nearby, which does not
include exon B, was also generated (Figure 1a, and
Supplementary Figure S1-A). The effects of MVaf1 and
MVcf expression on proliferation rates were evaluated
(Figures 1b–c). The number of cells expressing enhanced
green fluorescent protein (EGFP)-MVaf1 decayed drastically
after 18 h of transfection, in contrast to EGFP-MVcf or EGFP.
Even so, cultures expressing EGFP-MVcf and EGFP
experienced a growth delay, which may have been caused
by confluence or an underestimation of cell number in the
more populated (control) plates under the stereomicroscope.
In addition, attenuation of growth is less evident for EGFP
than EGFP-MVcf-expressing cells, although cells undergoing
apoptotic death were not observed (Supplementary
Figure S1-E). Concomitant to cell loss, EGFP-MVaf1 protein
levels progressively declined, whereas EGFP increased
(Figure 1d). Propidium iodide (PI) labeled a high percentage
of cells in the EGFP-MVaf1-transfected cultures (Figure 1e),
indicating that loss of fluorescent signal was due to cell
death. To investigate whether cell death was triggered by a
specific sequence within MVaf1, we analyzed the effect of
two additional constructs, EGFP-MVaf2 and EGFP-MVaf3.
Interestingly, EGFP-MVaf2 expression caused a large drop
in cell number, whereas EGFP-MVaf3 expression showed
negligible effects (Figures 1f and g). In contrast to MVaf3,
MVaf1 and MVaf2 contain exon B, indicating that the
presence of exon B was required for cell death. Conversely,
exon D, which is partly present in MVaf1 but not in MVaf2
and MVaf3, was not required.
MVaf1 expression induces apoptosis. Morphological
changes caused by EGFP-MVaf1 expression were charac-
terized by fluorescence microscopy, in Z-stack acquisition
mode (Figure 2a). EGFP-expressing control cells exhibited
flattened shapes, stress fibers, and normal nuclear size and
shape. Conversely, cells expressing EGFP-MVaf1 were
round, exhibited plasma membrane blebs, a peripheral
F-actin ring, as well as lack of stress fibers and loss of
contact with the substrate. After 20 h of transfection, B70%
of cells expressing EGFP-MVaf1 exhibited pyknotic nuclei.
Time-lapse microscopy of cells expressing EGFP-MVaf1
provided images of membrane blebbing, followed by cell
condensation and fragmentation into apoptotic bodies in a
10-min period (Figure 2b and Supplementary video). These
morphological features were not observed in EGFP control
cells (Figure 2b and Supplementary video). For a detailed
analysis of cell surface, we performed scanning electron
microscopy (SEM) of EGFP-MVaf1-transfected cells on Cell
Locate coverslips (Figure 2c). Figure 2c and Supplementary
video show pair of cells in an advanced stage of apoptosis,
undergoing a budding process, followed by separation of cell
fragments into apoptotic bodies. DNA fragmentation was
also assessed by TUNEL staining (Figure 2d). Representa-
tive phase contrast and red fluorescence images show that
36.6% of cells expressing EGFP-MVaf1 were TUNEL
positive (red), in contrast to 6.9% of EGFP-expressing cells,
48 h post transfection.
MVaf1 binds to DLCs and co-localizes with DLC2. To
gain further mechanistic insights into the observed induction
of apoptosis, we assessed the ability of MVaf1 or MVcf to
interact with DLCs. Pull-down assays were performed using
bacterially expressed and purified proteins fused to either
glutathione-S-transferase (GST) or maltose-binding protein
(MBP) (Figure 3a). Immobilized GST-MVaf1, like full-length
myosin-Va MT (GST-MT) exhibited binding to MBP-DLC2,
whereas GST-MVcf did not. Also, immobilized GST-MVaf1
and GST-MT captured EGFP-DLC1 or EGFP-DLC2 from
HEK293 cell lysates (Figure 3b). Confocal microscopy of
cells transfected with either EGFP-DLC2 or DsRed-MVaf1
showed that fusion protein is usually distributed throughout
the cell (Figure 3c, top panel). In co-transfected cells, fusion
proteins co-localized (92% index) and were mostly retained
in the cytoplasm (central and bottom panels). Next, we aimed
to minimize MVaf1-induced cell death by co-expressing
DLC2. Co-expression of DLC2 protected against the effect
of MVaf1 (Figure 3d). These observations are indirect
evidence that MVaf1 exerts its apoptotic effect by sequester-
ing DLC2.
MVaf1 and full-length myosin-Va medial tail sequester
DLCs, but are unable to co-capture Bmf. Based on
evidence that DLC2 works as an adaptor protein between
myosin-Va and Bmf, we investigated the ability of MVaf1 to
form a trimeric complex with DLC2 and Bmf using pull-down
assays (Figures 3e–g). Firstly, we found that GST-DLC2
binds to Bmf with a far greater affinity than GST-DLC1
(Figure 3e) and showed that DLC2 can co-capture EGFP-
Bmf and EGFP-Bcl2 present in cell lysates from HEK-293T
(Figure 3f). Taken together, these data suggest the formation
of a DLC2-Bmf-Bcl2 complexes, confirming previous evi-
dence of this trimeric complex formation,10 and that Bmf
binds DLC2 selectively.16 Next, EGFP-DLC2 or EGFP-DLC1
were co-expressed with EGFP-Bmf in HEK293T cells, and
the soluble extracts were incubated with glutathione resin
containing immobilized GST-MT or GST-MVaf1. Although
GST-MVaf1 and GST-MT unequivocally bound EGFP-DLC1
and EGFP-DLC2, Bmf remained in solution (Figure 3g). This
indicates DLC2 did not function as an adapter protein
between MVaf and Bmf. Also, preliminary assays (data not
shown) suggest that co-expression of MVaf1 with DLC2 and
Bmf halted the formation of the trimolecular complex
between DLC2, Bmf, and immobilized GST-Bcl2. These
data suggest that Bmf binds to Bcl2, but DLC2 remains in the
soluble fraction together with MVaf1.
Multiple cell lines are sensitive to MVaf1-triggered cell
death and may be influenced by myosin-Va/DLC2 levels.
As in B16-F10 cells, EGFP-MVaf1-induced cell death in two
human melanoma cell lines, WM35 and WM902 (Figure 4a).
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Population decline was delayed in WM902 (48 h), suggesting
that this line is more resistant than WM35 to death induced
by EGFP-MVaf1. Expression levels of MYO5A and DLC2
mRNAs were 1.4-fold and 2-fold, respectively, higher in
WM902 cells than in WM35 cells (Figure 4b), which can
account for the relative resistance of WM902. Nonetheless,
unrelated genetic alterations could account for this differ-
ence, as WM902 is derived from a tumor of a more advanced
Figure 1 MVaf expression reduces melanoma cell viability in an exon B-dependent manner. (a) Schematic diagram representing the primary structure of myosin-Va heavy
chain shows the positions of the structure sub-domains (H, head; N, neck; PT, proximal tail; MT, medial tail; GT, globular tail) and the DLC2 binding site in the MT domain, with
exon combination A, B, C, D, E and F. Exons B, D, and F are subject to alternative splicing. Detail: schematic diagram of selected segments for recombinant constructs.
EGFP–MYO5A(1276–1328[þB]) fragment (MVaf1), and variants, MVaf2(1255–1320[þB]) and MVaf3(1255–1320[-B]). EGFP–MYO5C(1179–1232) construct was used as a control and
comprised a region with low sequence conservation between the two paralogs (myosin-Va and -Vc). (b) Representative images of B16-F10 cell cultures, 18 and 72 h post
transfection with pEGFP, pEGFP-MVcf and pEGFP-MVaf1. Images were acquired under a fluorescence stereomicroscope. (c) Proliferation rates were determined as the
average number of fluorescent cells per area of growth (mm2) after 8, 18, 48 and 72 h post transfection. ***Statistic significance (Po0.001). Kinetics of recombinant protein
expression levels: (d) EFGP expression in B16-F10 cell lysates was quantified through ImageJ software analysis of western blots generated with an anti-EGFP (bottom panel)
relative to g-tubulin, a loading control (top panel). (e) Viability of cells expressing EGFP-MVaf1 or EGFP was determined by PI staining of dead cells at indicated times post
transfection. ***Statistically significant mean difference between EGFP and EGFP-MVaf1 groups (Po0.001). (f) Representative images of cultures taken 18 and 96 h post
transfection with pEGFP (control), pEGFP-MVaf1, pEGFP-MVaf2 or pEGFP-MVaf3. (g) Proliferation rates of B16-F10 cell cultures expressing either EGFP (control), EGFP-
MVaf1, EGFP-MVaf2 or EGFP-MVaf3 were determined as the average number of fluorescent cells per area of growth (mm2), per dish (n¼ 3) at 8, 18, 48, 72 and 96 h post
transfection. **Statistically significant mean difference between control (EGFP) and test groups (EGFP-MVaf1 and EGFP-MVaf2) (Po0.01)
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Figure 2 Cells expressing MVaf1 developed morphological features of apoptosis. Fluorescence and correlative light microscopy (LM)/SEM images are shown of B16-F10
cells, expressing either EGFP-MVaf1 or EGFP (control). (a) Fluorescence images show EGFP, F-actin (Phalloidin-Rhodamine) and nuclei (DAPI) staining. EGFP-MVaf1-
expressing cells (*) lack stress fibers, prominent in control cells (4, o), and display a peripheral F-actin ring, as seen in the single section image (insert, arrow). (b) Time-lapse.
B16-F10 cells grown on glass-bottom microwell dishes (F 35 mm) and transfected with pEGFP-MVaf1 or pEGFP (control). (c) SEM images of B16-F10 cells transfected with
pEGFP-MVaf1. B16-F10 cells grown on CELLocate-microgrid glass coverslips were imaged by LM, 24 h post transfection. SEM images of the corresponding cells were taken in
two subsequent magnifications. Transfected cells exhibit apoptotic features typical of late execution phase, such as loss of attachment and plasma membrane blebs. (d) Apoptotic
response to EGFP-MVaf1 involves DNA fragmentation. Detection of DNA fragmentation in suspended B16-F10 cells was assessed by the TUNEL assay. Scatter dot plot with
mean±S.E.M. showing the ratio of TUNEL-positive nuclei to total nuclei counts in EGFP- and EGFP-MVaf1-expressing cultures (n¼ 10 fields). Each data point represents a pair
of images, i.e., one field. ***Statistically significant mean difference between EGFP and EGFP-MVaf1 groups (Po0.001). Right panel shows representative differential
interference contrast (DIC) and TUNEL stain (red) images of a single field from either EGFP and EGFP-MVaf1-expressing cultures
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stage (vertical growth phase) than WM35 (radial growth
phase), and cancer cells accumulate a diverse array of
genetic mutations. Subsequently, we asked how sensitive
murine Cloudman S91 melanoma cells (derived from dilute
viral mouse) would be to apoptosis triggered by EGFP-MVaf1,
considering that this cell line is virtually free of myosin-Va
Figure 3 Protein interaction and co-expression assays. (a) MVaf1, but not MVcf, interacts with DLC1 and DLC2 in vitro. Bacterially expressed and purified GST or GST
fusion proteins immobilized on Glutathione-Sepharose 4B beads were incubated with 200 ng (*) and 800 ng (**) of purified MBP-DLC2 proteins or MBP alone. Full-length
myosin-Va MT fused to GST (GST-MT) was used as a positive control for interaction with DLC2. The purified proteins were separated on 5–20% SDS-PAGE gel and stained
by Coomassie blue (top panel). The migration positions of the molecular mass markers (kDa) are indicated on the left hand side. Pulled down proteins were blotted with anti-
DLC2 and anti-PIN antibodies (bottom panel). Black arrowheads indicate the migration position of MBP-DLC2. (b) GST pull-down experiments for MVaf1 and DLC1 or DLC2.
Bacterially expressed and purified GST-MVaf1 and GST-MT fusion proteins immobilized on Glutathione-Sepharose 4B beads were incubated with cell lysates from HEK-293T,
expressing either EGFP-DLC1, EGFP-DLC2 or EGFP alone. Proteins from pull-down interactions or post-pull-down supernatants were separated on 5–20%
SDS-PAGE gel and stained by Coomassie blue (top panel). Western blots were probed with anti-EGFP and anti-PIN antibodies (bottom panels). Black arrowheads indicates
EGFP-DLC 1 or 2, and white arrowhead indicates EGFP. (c) DsRed-MVaf1 co-localizes with EGFP-DLC2 in the cell cytoplasm. B16-F10 cells expressing either (top panel), or
both (central panel) EGFP-DLC2 and DsRed-MVaf1, were fixed and imaged by confocal microscopy. Colocalization was analyzed using Leica LAS-AF software. (d) Co-
expression of DLC2 with MVaf1 attenuates MVaf1-induced cell death. Proliferation rates of B16-F10 cell cultures expressing either EGFP (control), EGFP-MVaf1, EGFP-
DLC2 or co-expressing EGFP-MVaf1 and EGFP-DLC2 were determined as the average number of fluorescent cells per area of growth (mm2), per dish (n¼ 4), after 8, 18, 48
and 72 h post transfection. (e-g) GST pull-down experiments for investigating the interactions between MVaf1, DLCs, Bmf and Bcl2. Bacterially expressed and purified GST
fusion proteins (as indicated) were immobilized on Glutathione-sepharose 4B beads and incubated with cell lysates from HEK-293T expressing EGFP-Bmf alone (e), or the
combination of EGFP-Bmf plus EGFP-Bcl2 (f), or EGFP-Bmf plus either EGFP-DLC1 or EGFP-DLC2 (g). Proteins from pull-down interactions were separated on 5–20%
SDS-PAGE gel and stained by Coomassie blue (top panels). Western blots were probed with anti-EGFP (bottom panels) or anti-Bcl2, as indicated. Note strong interaction of
Bmf with DLC2 and only a poor interaction with DLC1. Also note that immobilized DLC2 bound Bmf/Bcl2, whereas immobilized myosin-Va tail fragments pulled-down DLCs but
left behind Bmf in the supernatant, indicating that DLC2 was unable to play an adaptor function
A myosin-Va fragment triggers apoptosis
TC Izidoro-Toledo et al
5
Cell Death and Disease
expression. The number of EGFP-MVaf1-expressing cells
decayed very rapidly from 18 to 96 h, such that cultures
remained with only 5% of cells initially scored at 18 h
(Figure 4c). PI staining confirmed intense cell death
(Figure 4d). The levels of DLCs were equivalent between
S91 and B16 cells (Figure 4e), indicating that the higher
sensitivity of S91 to EGFP-MVaf1-induced death was not due
to reduced DLC1/2 levels. We hypothesize that trapping of
DLCs by MVaf1 is more effective because MVaf1 is not
counteracted by the endogenous pro-survival myosin-Va in S91
Figure 4 Human melanoma cell lines are prone to cell death triggered by MVaf1 and levels of myosin-Va/DLC2 appears to influence cell death sensitivity. (a). Proliferation
rates of WM35 and WM902 cells expressing either EGFP (control) or EGFP-MVaf1 were determined as the average number of fluorescent cells per area of growth (20 random
fields of 1.6 mm2 per dish; n¼ 4), after 8, 18, 48, 72 and 96 h of transfection. Rates are expressed as a percentage increase or decrease in culture proliferation from 18–96 h
(WM35) or 48–96 h (WM902) post transfection (on the right-hand side of proliferation curves). (b) Northern blot analysis. MYO5A and DLC2 gene expression profiles in human
melanoma cell lines WM35 and WM902. Densitometry of the specific bands was done measured by the ratio of pixel intensity (relative signal) using ImageJ gel analysis
software; b-actin mRNA was used as the loading control. (c) Proliferation rate of Cloudman S91 mouse melanoma cells (bearing a MYO5A loss-of-function mutation)
expressing either EGFP (control) or EGFP-MVaf1. Rates expressed as percentage increase or decrease in proliferation from 18 to 72 h post transfection are indicated. (d) Cell
death rates for Cloudman S91 cells expressing EGFP-MVaf1 and EGFP were determined by PI staining at 24, 48, 72 and 96 h post transfection. After imaging 20 random
fields per dish (n¼ 5), the percentage of unviable cells was calculated relative to the total number of green fluorescent cells. (e) Detection of DLCs in
B16-F10 and S91 cell lysates. Cell lysates from B16-F10 and Cloudman S91 were collected, equivalent amounts of total protein was loaded and analyzed by electrophoresis
on a 5–20% SDS-PAGE, stained with Coomassie blue (top panel). Anti-DLC/PIN, which recognizes both DLC 1 and 2, was used as detection antibody (bottom panel). bMVa,
purified fraction of native myosin-Va from chick brain, was used as positive control for the detection of the light chain DLC2 (as indicated)
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cells. In addition, this result implies that DLC2 probably also
functions to promote cell survival independently of myosin-Va.
MVaf-induced apoptosis is associated with cytochrome-
c and Smac release as well as caspase-9/-3 activation.
To evaluate whether EGFP-MVaf1 triggers apoptosis
through the intrinsic pathway by inducing mitochondrial outer
membrane permeabilization (MOMP), we investigated the
occurrence of cytochrome-c release. The number of cells
with a diffuse cytochrome-c staining pattern was higher
among EGFP-MVaf1-expressing cells than among EGFP
control or non-transfected neighbors. Diffuse cytochrome-c
pattern increased from 14 to 41.4% in the 24–33 h interval
post transfection with EGFP-MVaf1, whereas reached only
8.6% rates in EGFP cells (Figure 5a). Subsequently, we
monitored MOMP by Smac–Cherry release using time-lapse
microscopy in cells co-expressing EGFP-MVaf1 and Smac–
Cherry (Figure 5b and Supplementary video). EGFP-MVaf1
was intense and distributed throughout the cell, whereas
Smac-Cherry changed from compartmentalized in mitochon-
dria (punctate labeling) to a diffuse staining pattern. Soon
after, cells exhibited characteristic features of apoptosis,
such as membrane blebbing, loss of adhesion, and nuclear
condensation, which culminated in fading of fluorescence.
Caspase-9 activation was involved in the apoptotic response
triggered by EGFP-MVaf1, as the cleaved form of caspase-9
(37-kDa band) was predominant and the full-length form was
less pronounced in lysates of cells expressing EGFP-MVaf1
than in control cell lysates (Figure 5c). The signal intensity
ratio between active caspase- and pro-caspase-9 was about
sixfold higher in EGFP-MVaf1-expressing cells. To deter-
mine caspase-3 activation, we utilized a caged fluorochrome
conjugated to caspase-3 substrate (Figure 5d and
Supplementary video). EGFP-MVaf1-expressing cells turned
bright red fluorescent, denoting a sudden activation of
caspase-3. This was immediately followed by plasma
membrane blebbing cellular fragmentation and plasma
membrane rupture, accompanied by an accentuated drop
in green fluorescence. The whole process was completed in
about 2 minutes.
Bmf/Bim and Bax/Bak are important but ultimately
not essential for the apoptosis triggered by MVaf
expression. To evaluate whether Bim/Bmf or Bax/Bak are
required for the apoptotic response triggered by EGFP-
MVaf1, we compared rates of apoptosis in wild-type (WT)
murine embryonic fibroblasts (MEFWT) with Bmf/Bim or
Bax/Bak double-knockout MEFs by scoring dead cells
through video microscopy. Figure 5e represents the percen-
tage of dead cells. MEFWT showed the highest scores of
cell death (90%). Conversely, double-knockout strains were
less sensitive to induced cell death, with scores of 45%
for MEFsBim / ,Bmf / , and 30% for MEFsBax / ,Bak / .
We also assessed the occurrence of Smac release in
MEFsBax / ,Bak / , co-expressing EGFP-MVaf1 and
Smac-Cherry. It was observed that cells at 31 h post
transfection were still exhibiting a punctate Smac-Cherry
labeling, although displaying morphological features of
apoptosis (Figure 5f). MEFWT underwent MOMP similar to
B16-F10 melanoma cells (not shown).
MVaf1 expression hinders growth of B16-F10 solid
tumors in mice. To assess the effect of MVaf1 expression
on tumor growth we used a xenograft murine model. Tumors
expressing EGFP appeared earlier and grew faster than
tumors expressing EGFP-MVaf1, regardless of whether mice
were treated with doxycycline or not (Figures 6a and b). With
regard to tumors carrying EGFP-MVaf1, we observed that in
animals not receiving doxycycline tumors developed earlier
and were larger than in treated animals. Nevertheless, in the
absence of doxycycline, EGFP-MVaf1 tumors did not grow
comparably to controls, possibly due to expression leakage,
which was confirmed by western blots of solid tumor lysates
(Figure 6c). Sorted EGFP-MVaf1 cells and EGFP control
consisted of mixed populations, not clonal lineages, making
unlikely that genomic integration could account for these
results, as genetic alterations leading to unfavorable growth
are not prone to be selected for in the population. Next,
survival rates of mice injected with parental cells were
compared with those injected with two distinct strains of
EGFP-MVaf1-transduced cells, which were derived from
single cell-isolated clones C3 and G3 (Figure 6d). Mice
expressing EGFP-MVaf1 survived longer than control.
In addition, we evaluated whether EGFP-MVaf1 would
influence/susceptibility to conventional chemotherapeutic
drugs (Supplementary Figure S1-F). After treatment with
paclitaxel or etoposide, EGFP-MVaf1-expressing cells dis-
played 54 and 39% more apoptotic cells than controls
(Supplementary Figure S1-F), suggesting that EGFP-MVaf1
expression sensitizes cells to chemotherapy. Western blots
show the levels of EGFP-MVaf1 expression in the cultures
analyzed (Supplementary Figure S1-G). Finally, clonogenic
assays with stably transduced B16-F10 cells (Supplementary
Figure S1-H) corroborated the notion that expression of
MVaf1 restores susceptibility to apoptosis.
Discussion
Despite the suggested involvement of myosin-Va/DLC2
motor complex in anoikis-induced cell death, its roles in
cancer remain largely unexplored. Resistance to anoikis
leads to anchorage-independent growth and malignant
transformation.12–14,17 In this work, we initially aimed at
cloning the less conserved regions among the three myosin-
V paralogs for functional studies. It was soon apparent that the
expression of EGFP-MVaf1 led to a dramatic decline in the
number of transfected cells due to apoptosis induction, as
suggested by morphological features18 and molecular events
typical of apoptosis. Release of cytochrome-c and Smac
supports the involvement of MOMP, with subsequent activa-
tion of caspase-9/-3, in the MVaf1-induced apoptotic
response. However, EGFP-MVaf1 did not seem to localize
to mitochondria, suggesting that MOMP was an indirect
consequence of MVaf1 action. Accordingly, we found that
MVaf1 binds DLC2, which potentially impedes the docking of
Bmf onto the actin cytoskeleton. This is further supported by
the fact that MEFs lacking Bim/Bmf or Bax/Bak were less
susceptible to induced cell death than MEFWT, suggesting the
requirement of these pro-apoptotic proteins as mediators of
MVaf-induced MOMP. Attenuation of apoptosis in MEFs
lacking Bmf/Bim suggests a mechanistic interaction similar
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to the one previously proposed by Puthalakat and
co-workers.10,11 Nevertheless, Smac remained compartmen-
talized in dying MEFsBax / ,Bak / and apoptosis was not
completely abolished in MEFs lacking Bim/Bmf, indicating
that high expression of MVaf1 triggers cell death through
multiple intracellular mediators and pathways.
Remarkably, Bmf sequestration to the actin cytoskeleton
through DLC2 was reported to be involved with resistance
to MEK inhibitors in melanoma cells, so that overexpression
of Bmf in resistant cells does not induce apoptosis,
whereas mutant BmfA69P, with decreased DLC2 binding,
promotes cell death.19 In addition, acquired resistance
of human melanoma cells toward the oncogenic BRAF
inhibitor PLX4032 (vemurafenib) was associated with
epigenetic silencing of Bim and Bmf.20 Consistently, we
demonstrated herein that MVaf1 expression hindered
melanoma growth and increased survival in mice. Further-
more, we demonstrated that EGFP-MVaf1 expression
A myosin-Va fragment triggers apoptosis
TC Izidoro-Toledo et al
8
Cell Death and Disease
sensitizes B16-F10 cells to paclitaxel and etoposide,
suggesting that MVaf1 could have a significant role as a
co-adjuvant against chemoresistant cells.
Interestingly, emerging evidence implicates myosin-Va in
cell survival and cancer-promoting functions. Myosin-Va was
found in a complex with Bcl-xL, which has been suggested to
Figure 6 Effects of MVaf1 expression on tumor growth and animal survival rate in the B16-F10-bearing murine model. (a) Tumor growth rates. Mice bearing EGFP-MVaf1-
expressing cells and treated with doxycycline (doxy) did not develop tumors until after the 24-day observation period. Significant differences were verified using an unpaired
two-tailed Student’s t-test. (*) Po0.05 compared with controls, as indicated on the figure. (b) Representative images of mice bearing tumors of EGFP-MVaf1 and EGFP-
transduced B16-F10 cells. The B16-F10 melanoma tumor incidence rate and size were dramatically decreased by EGFP-MVaf (± doxy). Arrows show the site for EGFP-
MVaf1-expressing tumor (black) and EGFP-expressing tumor (gray) (n¼ 8/group). (c) Western blots of solid tumor lysates. Lysates were prepared 30 days post inoculation
and were probed with commercial anti-GFP antibody (a-EGFP) and laboratory-made anti-MVaf (a-MVaf); g-tubulin was used as loading control. Black arrowheads indicate
EGFP-MVaf1 and white arrowhead indicates EGFP. Analysis shown in a–c were done with whole populations of EGFP-MVaf or EGFP-transduced cells. (d) Survival rates of
mice bearing subcutaneous tumors of parental B16-F10 cells or derived clones (C3 and G3) expressing EGFP-MVaf. The survival rates and survival time increased in both
C3þ doxy and G3þ doxy groups (n¼ 6, in observation time point: 66 days post inoculation) compared with the B16þ doxy control group (no animal survived beyond
30 days). C3 and G3 are single-cell clones of EGFP-MVaf1 derived from transduced B16-F10 cell
Figure 5 Cells expressing MVaf1 undergo mitochondria-mediated apoptosis. (a) Immunolocalization of Cyt-c. B16-F10 cells expressing either EGFP-MVaf1 or EGFP
(control) were stained by immunocytochemistry with anti-Cyt-c antibody. Cells displaying a diffuse cytosolic Cyt-c staining were counted among 10 random fields per coverslip,
and the percentage of cells with released Cyt-c was calculated relative to the total number of green fluorescent cells. Right panel shows representative images of cells,
expressing either EGFP or EGFP-MVaf1, 33 h post transfection. In most cells expressing EGFP (control), Cyt-c staining showed an abundant and granular perinuclear pattern
indicating mitochondrial compartmentalization. EGFP-MVaf1-expressing cells showed more diffuse red fluorescence pattern indicating their release into cytosol (scale bar:
10mm). (b) Smac-Cherry time-lapse. B16-F10 cells were co-transfected with pEGFP-MVaf1 and pSmac-Cherry. In the example shown, at 27 h post transfection, Smac-Cherry
(red) is still compartmentalized in mitochondria. At 27 h and 20 min, Smac-cherry displays a widespread distribution within the cell. At 28 h, cells lost their fluorescence.
(c) Western blot for caspase-9. Cell lysates from B16-F10 cells expressing either EGFP-MVaf1 or EGFP (control) were collected at 24, 36, 48 and 60 h post transfection,
combined and analyzed by western blotting with anti-caspase-9, as detection antibody. Duplicates were run for each sample. (c, top) Bands corresponding to pro-caspase-9
(47 kDa) and caspase-9 (37 kDa), were identified in all samples; black arrowhead indicates a nonspecific cross-reacting band picked up by caspase-9 antibody, and served as
loading control. (c, bottom) Graphical representation of the relative intensity of pro-caspase- and caspase-9 bands measured by the ratio of pixel intensity using ImageJ gel
analysis software. (d) Caspase-3 activation. Frames selected from video acquired by time-lapse confocal microscopy. At 24 h post transfection with pEGFP-MVaf1 or pEGFP
(control), B16-F10 cells were treated with caspase-3 Fluorogenic Substrate IX (Calbiochem) and (Z-DEVD)2–Rh110 for 10 min in order to monitor caspase-3 activity.
(e) Scoring of apoptotic MEFs. Representative sequence of a 2.5-h exposure time-lapse of MEFWT, MEFBax / ,Bak / and MEFBim / ,Bmf / transiently transfected
with pEGFP-MVaf1 and imaged 24 h later. Data is represented as percentage of dead cells relative to the total number of green fluorescent cells. Ten independent time-lapse
recordings were acquired for each cell line. (f) Smac–Cherry release from MEFBax / , Bak / mitochondria. Bax/Bak double-knockout murine embryonic cells were co-
transfected with pEGFP-MVaf1 and pSmac-Cherry. Images represent excerpts from DIC and fluorescence microscopy videos of a representative cell expressing EGFP-
MVaf1. In the example shown, at 31 h and 20 min post transfection, Smac-Cherry (red) is still compartmentalized in mitochondria of the dying cell (observed as a punctate
staining pattern). Wild-type MEFs underwent permeabilization of the mitochondrial outer membrane similar to B16-F10 melanoma cells (not shown). So MOMP is involved but
ultimately does not appear to be crucial for the occurrence of cell death
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promote aggressive behavior of islet tumor cells.21 Myosin-Va
was proposed as a useful biomarker of invasiveness for non-
functioning pituitary adenomas,22 and upregulation of myosin-
Va by Snail has been correlated with cancer metastasis.23
Other intriguing findings involving myosin-Va could as well
contribute to death resistance and other hallmarks of cancer.
For instance, myosin-Va was involved in the transport of
PTEN to the plasma membrane, thereby modulating PI3K
pathway neuronal cells,24 in plasma membrane receptor
recycling,25 and trafficking of the glucose transporter GLUT4
in adipocytes.26 Concurrently, GLUT4 has been claimed
to function in cancer cells.27 Myosin-Va was also shown to
localize to the centrosome and mitotic spindle,28 and to
nuclear speckles,29 which may be linked to a putative role in
the transport of mRNA.30 Interestingly, recent data from our
group reveal that in comparison to melanocytes, various
melanoma cell lines show strong upregulation of myosin-Va,
and its depletion with shRNAs attenuates anchorage-inde-
pendent growth and invasion in vitro (Alves et al., manuscript
submitted), compatible with the notion that myosin-Va
contributes to anoikis resistance. Here, we found that S91
melanoma cells (virtually free of myosin-Va) were remarkably
sensitive to EGFP-MVaf1-induced cell death. Consistently,
S91 cells were previously reported to be surprisingly sensitive
to anoikis, accounting for the poor metastatic ability of this cell
line.17 We understand that in the absence of endogenous
myosin-Va to compete for DLC2, MVaf is more effective in
sequestering the light chains and, consequently, unleashing
the pro-apoptotic factors. On the other hand, this result
denotes that DLC2 probably also functions to promote cell
survival independently of myosin-Va, by direct interaction with
Bmf and/or additional partners.3
We demonstrated that MVaf1, which contains the core of
DLC-binding site, binds both DLC2 and DLC1, but the
complex MVaf1/DLC2 was unable to bind Bmf, suggesting
that induction of apoptosis by MVaf1 is due to sequestration of
DLC2, and probably also DLC1. As a result, both pro-
apoptotic molecules, namely Bmf and Bim, would be
unleashed and stabilized in the cytosol, allowing interaction
with mitochondrial anti-apoptotic Bcl2 family members and
consequent launch of apoptosis, as proposed in our sche-
matic model (Figure 7). Also, Bim may directly activate Bax/
Bak as reported previously.31,32 The hypothesis postulated
here is strongly supported by previous observations10,11 and
may possibly explain the intense apoptotic response to
MVaf1, resulting from concomitant action of both pro-
apoptotic proteins. These findings are equally corroborated
by the dependence of MVaf1-induced apoptosis on the three
amino acid residues DDK, encoded by exon B, which was
shown to be required for DLC binding by Hódi et al.15 and
Wagner et al.33 The postulated model also integrates several
studies on pro-survival and pro-apoptotic kinase signaling
pathways controlling Bim and Bmf activity, and attempts to
explain how such mechanisms may contribute to the intense
apoptotic response induced by MVaf1. Treatment of epithelial
cells with epidermal growth factor (EGF) has been shown to
protect against UV-induced apoptosis, by the activation of
p21-activated kinase (PAK1).34 EGF-activated PAK1 phos-
phorylates both DLC1 and Bim, inducing their dissociation and
preventing the function of Bim by targeting it for proteasomal
degradation. Furthermore, PAK1 was also demonstrated to
interact with DLC2.35 We hypothesize that overexpressed
MVaf1 binds DLC1 and DLC2, preventing them from binding
their respective partners Bim and Bmf. Consequently, both
pro-apoptotic proteins would not be targeted for degradation.
Instead, they would be available for the pro-apoptotic or
stress-activated c-Jun N-terminal kinase (JNK) that phos-
phorylates unbound Bim and Bmf, stabilizing them by
Figure 7 Hypothetical model of the mechanism by which MVaf1 overexpression induces apoptosis. It has been previously demonstrated that after apoptotic stimuli, EGF-
activated PAK1 phosphorylates both DLC1 and Bim, inducing their dissociation and targeting the pro-apoptotic protein for degradation by the ubiquitin-proteasome system,
thus promoting survival.31,32 Furthermore, PAK1 has also been demonstrated to interact with DLC2.33 Investigation of protein connections by pull-down assays suggests that
upon high levels of expression, MVaf1 would sequester both DLC1 and DLC2, preventing them from binding their respective partners Bim and Bmf. Hence, both pro-apoptotic
proteins would not be targeted for degradation by PAK1. Instead, they would be available for the pro-apoptotic or stress-activated JNK that phosphorylates unbound Bim and
Bmf, preventing their ubiquitination.34,35 Stabilized Bmf, and possibly Bim, would finally trigger apoptosis via mitochondria-mediated pathway
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preventing their ubiquitination.36 Bim and Bmf were shown to
be essential for anoikis and suppression of Bmf by oncogenes
was required for transformation of MCF10A mammary cells.37
Similarly, Bim and Bmf mediate apoptosis in response to MEK
inhibitors and sequestering of Bmf leads to drug resistance.19
Also, Bim and Bmf were found to act in concert to induce
anoikis-like apoptosis in HeLa cells infected with Neisseria
gonorrhoeae.38 Infection-induced loss of Bim and Bmf from
the cytoskeleton fraction required the activation of JNK-1.
Accordingly, depletion/inhibition of JNK-1, Bim or Bmf
prevented the activation of Bax/Bak. Moreover, cooperation
between Bmf and Bim in vivo was demonstrated.39 Alto-
gether, these data support our hypothetical model.
Despite sharing 93% sequence identity, it has been
demonstrated that both DLCs show unambiguous specificity
for their respective BH3-only ligands and motor complexes.16
Nevertheless, myosin-Va has identical binding characteristics
to recombinant DLC1 or DLC2 in vitro.5 The contrast between
in vivo-and in vitro-binding specificity suggests an intrinsic
molecular mechanism or the involvement of other proteins for
the specific compartmentalization of DLCs and their pro-
apoptotic cargoes.16 Hence, it is possible that the small
soluble recombinant fragment MVaf1 is not subjected to
specific DLC-compartmentalization rules. Furthermore, the
remarkable apoptotic effect triggered by MVaf raises a central
question for future investigation: Is it possible that upon
apoptotic stimuli, cells naturally produce a similar molecule?
This would not be surprising, because many cellular functions
are controlled by the formation of biologically active proteolytic
fragments,40–43 and a precedent that supports this idea is that
myosin-Va bears a calpain cleavage region, downstream of
the strong PEST motif, in the medial tail.44–47
In conclusion, this work provides a proof of the concept that
Bmf is kept in check by interaction with myosin-Va/DLC2,10
and disruption of this interaction leads to apoptosis. Yet, data
shown here suggest that further studies are needed to clarify
the exact role for myosin-Va in this process. In any case, our
results reinforce previous findings19,34,37 that the restraining
mechanism provided by DLC1/2 on BH3-only molecules may
have a role in malignant transformation and drug resistance.
This is the first demonstration that targeting this anti-apoptotic
mechanism by an exogenous molecule shifts the balance
towards apoptosis. Therefore, MVaf may be applied as an
apoptosis-inducing tool for chemoresistant cancer cells,
opening new avenues for future investigations in this field.
These findings also raise the potential of developing novel
therapeutic drugs based on the rational shown here, aiming at
clinical application.
Material and Methods
Cell lines and culture. Murine melanoma cell lines B16-F10 (derived from
C57BL/6J mouse, D/D, B/B), carrying WT MYO5A gene, and S91-6 (isolated
from a DBA/2J mouse dv/dv, b/b), carrying the dilute MYO5A gene mutation
were generously provided by Dr. J. Pawelek (Yale University, New Haven, CT,
USA). Both cell lines were grown in Ham-F10 medium (Gibco-BRL, Gaithersburg,
MD, USA) supplemented with 10% heat-inactivated fetal bovine serum (FBS;
Invitrogen, Carlsbad, CA, USA) and antibiotics. Human melanoma cell lines
WM35 and WM902 (derived from primary tumors in the radial and vertical growth
phase, respectively) were generously provided by Dr. Meenhard Herlyn
(The Wistar Institute Cancer Center). They were cultured in TU 2% medium
containing 80% MCDB-153 (Sigma-Aldrich, St. Louis, MO, USA), 20% Leibovitz’s
L15 (Invitrogen), 2% heat-inactivated FBS, 5 mg/ml insulin and 1.68 mM
CaCl2 (both from Sigma-Aldrich).
48 MEFs with double-knockout for Bmf/Bim
(MEFsBim / ,Bmf / )39 and Bax/Bak (MEFsBax / ,Bak / )49 as well as
respective WT were kindly provided by Dr. Roger J Davis (Howard Hughes
Medical Institute, Massachusetts Medical School). Also, MEFs with knockout for
Bmf or Bim were kindly provided by Dr. Andreas Villunger (Innsbruck Medical
University, Austria) and Professor Andreas Strasser (Walter and Eliza Hall
Institute, Melbourne, Australia). All MEFs were cultured in Dulbecco’s modified
Eagle’s medium; Invitrogen) supplemented with 10% heat-inactivated FBS, 1%
non-essential amino acids (Invitrogen), 1% L-glutamine, 50 mM b-mercaptoetha-
nol, 20 mM HEPES and antibiotics. The human embryonic kidney cell line HEK-
293T/17 (CRL-11268 from ATCC) was cultured in Dulbecco’s modified Eagle’s
medium low glucose (Invitrogen) supplemented with 10% heat-inactivated FBS
and antibiotics. All cell cultures were maintained at 37 1C in a humidified
atmosphere of 5% CO2–95% air.
Expression constructs for MVaf and MVcf, and transfection.
Multiple alignments of the complete amino acid sequence from the three human
class V myosin members were performed, by means of the ClustalW program,
version 1.81 (Supplementary Figure S1-A). The lowest conserved regions among
the three class V paralogs were selected, reasoning that their expression in
mammalian cells would interfere with specific functions of each particular paralog
only. Fragments of about 50 amino acids long were defined in order to exclude
stretches of conserved sequences common to the three paralogs, and to have a
size enough to bare the core of a protein–protein interaction motif. MVafs and
MVcfs cloned to generate the fusion constructs are highlighted in Supplementary
Figure S1-A, and are also represented by line diagrams positioned beneath the
linear schematic for myosin-Va in Figure 1a. Myosin-Vb fragment was not included
in this study. Three MVafs were generated. The first fragment, termed MVaf1,
comprised amino acids 1276–1328 (53 amino acid residues) including parts of
exons A and D and all of exon B, and C. Note that the selected region for MVaf1
corresponds to the core of the DLC2-binding region.15,31 Two additional
constructs, termed MVaf2 and MVaf3 were generated in order to gain insights
into the requirement of tissue-specific exons for any observed effect. Constructs
MVaf2 and MVaf3 comprise amino acids 1255–1320 in NM_000259. MVaf2 is
composed of 66 residues, including part of exon A, and complete exon B, and C,
whereas MVaf3 encompasses 63 residues, excluding exon B. Such strategy
aimed to survey possible connections between the cell death mechanism triggered
by MVaf1 and DLC association. MVcf, termed MVcf, comprises amino acid
residues 1179–1232 of the predicted human myosin-Vc sequence (NM_018728).
All constructs had the correct sequences and expected fusion tags. EGFP-MVaf1
and EGFP (control) were immunoprecipitated from HEK-293 cell lysates with anti-
EGFP (Clontech, Mountain View, CA, USA). The expected molecular mass and
integrity of the fusion proteins were confirmed by SDS-PAGE (Supplementary
Figure S1-B) and western blot (Supplementary Figure S1-C) using anti-EGFP and
anti-myosin-Va antibodies. An antibody generated to GST-MVaf1 recognizes
endogenous brain myosin-Va (Supplementary Figure S1-D). The remaining
recombinant proteins used in this work were also checked for integrity by SDS-
PAGE and western blotting (data not shown).
PCR products for MVaf, MVcf and other constructs were prepared using cDNA
templates from different sources, such as human brain (MVaf1), HeLa (MVcf),
1205Lu melanoma cells (DLC2), B cells (Bmf), sk-mel melanoma cells (MVaf2 and
MVaf3), and clone EST63321 from ATCC (DLC1). RT-PCR products were cloned
into pUC18, pGEX2T, pGEX-4T-3 or pIH 902 vectors (Amersham Biosciences, GE
Healthcare, Uppsala, Sweden), as well as pEGFP-C1 and pDsRed1-C1 (Clontech).
Transfections of B16-F10, S91 and WM cells were performed with the SuperFect
transfection reagent (Qiagen, Valencia, CA, USA) according to the manufacturer’s
instructions. The transfection of HEK-293T cells was carried out using the calcium
phosphate co-precipitation technique.
Cell proliferation and viability assays. B16-F10, S91-6 and WM
melanoma cells were seeded on 35-mm glass-bottom dishes (7 104 cells/dish)
for 24 h, and transiently transfected as described above. Cultures (n¼ 5) were
imaged (20 random fields of 1.6-mm2 each/dish) on a Fluorescence Stereomicro-
scope LEICA MZFL3 (Leica Microsystems GmbH, Wetzlar, Germany), after PI
staining (Sigma-Aldrich, catalog no. P4170), using two channels of fluorescence
(green and red). Cell count was performed after periods of 8, 18, 48 and 72 h (or
96 h) post transfection. Viability was determined as the percentage of PI-positive
dead cells, calculated relative to the total number of green fluorescent-transfected
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cells using the ImageJ software (http://rsb.info.nih.gov). Alternatively, cells were
seeded on 24-well plates (1.2 104 cells/well), and cell counting was performed
directly under microscopic examination ( 40 objective, Nikon Eclipse TS100), by
scanning along five fixed lines.
Fluorescence and time-lapse microscopy; DNA fragmentation
and active caspase-3 detection assays; cytochrome-c and
Smac release assays. B16-F10 cells were cultured for 24 h on glass
coverslips coated with poly-D-lysine (Sigma-Aldrich), transfected with pEGFP-
MVaf1 or pEGFP (control) and incubated for more 24 or 48 h, when they were
fixed, permeabilized and labeled with 2mg/ml DAPI (Molecular Probes, Invitrogen,
catalog no. D1306) and 0.002 U/ml Rhodamine-conjugated Phalloidin (Molecular
Probes, Invitrogen, catalog no. R415), according to the manufacturer’s protocol.
For TUNEL assay, 48 h post transfection culture, dishes were gently shaken to
bring to suspension loosely adhered cells, which were then harvested by
centrifugation, resuspended in culture medium, distributed onto poly-D-lysine-
coated coverslips and centrifuged again at 38 g for 5 min at 4 1C to accelerate
cell adhesion. The TUNEL cell death assay was carried out using the ‘In Situ Cell
Death Detection Kit’ TMR red (Roche Applied Science, Indianapolis, IN, USA,
catalog no. 12156792910) according to manufacturer’s instructions. Cells were
imaged using a Zeiss Axiovert 100 inverted fluorescence microscope (Carl Zeiss,
Jena, Germany), in 10 random fields per coverslip using two channels of
fluorescence (green and red). The percentage of TUNEL-positive cells was
calculated as the ratio between TUNEL-positive and total number of cells counted
(B150 cells/coverslip). In order to monitor cytochrome-c release, B16-F10 cells
grown on poly-D-lysine-coated coverslips, and expressing either EGFP-MVaf1 or
EGFP were fixed and stained by immunocytochemistry with monoclonal
anti-cytochrome-c primary antibody (BD Biosciences, San Jose, CA, USA) and
Alexa Fluor 594 donkey anti-mouse IgG secondary antibody (Molecular Probes,
Invitrogen Corp., Eugene, OR, USA). Coverslips were mounted in Fluoromount G
(Electron Microscopy Sciences, Washington, PA, USA), imaged on an inverted
fluorescence microscope as previously described, and analyzed using the
Metamorph 4.1 program. The percentage of cells displaying a diffuse cytosolic
cytochrome-c staining was calculated relative to the total number of green
fluorescent cells. For time-lapse analysis of caspase-3 activity, B16-F10 cells
grown on glass-bottom microwell dishes (F 35 mm). coated with poly-D-lysine
were treated with caspase-3 Fluorogenic Substrate IX (Calbiochem, San Diego,
CA, USA) and (Z-DEVD)2–Rh110 for 10 min, 24 h post transfection. Cells were
imaged in CO2-independent medium (Invitrogen), by confocal microscopy, using a
Leica TCS-SP5 AOBS system, equipped with an incubator chamber. Red and
green fluorescence images were captured in two channels: EGFP ex/em max
488/509 nm; Rhodamine 110 ex/em max 494/521 nm. The distribution of the pro-
apoptotic mitochondrial protein Smac was assessed in 24 h cultures of B16-F10,
MEFWT and Bax/Bak double-knockout MEF cells, grown on coated glass-bottom
microwell dishes (F 35 mm) and co-transfected with pEGFP-MVaf1 (green) and
pSmac-Cherry (red). Cells were time-lapse imaged in CO2-independent medium
(Invitrogen), as described above, and those exhibiting morphological features of
cell death were scored and represented as percentage of dead cells relative to the
total number of green fluorescent cells. Ten independent time-lapses were
assessed for each cell line. For the analysis of MVaf1 and DLC2 colocalization,
live cells co-expressing DsRed-MVaf1 and EGFP-DLC2 were imaged at 24, 48, 72
and 96 h post transfection by confocal microscopy, as previously described.
Scanning electron microscopy. ForSEM, B16-F10 cells were cultured on
Cellocate coverslips (Eppendorf, Hamburg, Germany) with grid square size of
55mm. At 24 h post transfection, fluorescent cells on the Cellocate grid were
imaged under fluorescence and bright-field microscopy, so that the grid
coordinates were registered. They were then immediately fixed with 2%
glutaraldehyde in PBS containing 1 mM CaCl2 and 0.5 mM MgCl26H2O, for 2 h
at room temperature, rinsed in 0.1 M sodium cacodylate buffer, pH 7.4 and post-
fixed in 1% osmium tetroxide in the same buffer, for 2 h at room temperature,
rinsed five times in deionized H2O. Subsequently, samples were incubated with a
saturated solution of thiocarbohydrazide for 10 min in the dark, rinsed five times in
deionized H2O, followed by 1% osmium tetroxide for 30 min in the dark and rinsed
again. These steps were repeated once. Cells were dehydrated in a graded series
of ethanol and critically point-dried with liquid CO2 in a BAL-TEC-CPD 030 Critical-
Point Dryer (Bal-Tec AG, Balzers, Liechtenstein), mounted on aluminum stubs
with silver paint (EM Sciences) and coated with gold in a BAL-TEC SCD 050
Sputter Coater (BAL-TEC). Samples were examined in a JEOL JSM-5200 SEM.
Caspase-9 detection. Cell lysates from B16-F10 cells expressing either
EGFP-MVaf1 or EGFP were collected at 24, 36, 48 and 60 h post transfection,
combined, electrophoresed on 15% SDS-PAGE gel and measured by western
blotting for detection of pro-caspase-9 and caspase-9, using pAb anti-caspase-9
(BD Biosciences, catalog no. 552036) and goat anti-rabbit IgG, HRP-conjugate
(Pierce, Rockford, IL, USA) as secondary antibody. Quantification of the specific
bands from the western blotting was measured by the ratio of pixel intensity using
ImageJ gel analysis software (U. S. National Institutes of Health, Bethesda, MD,
USA).
Pull-down assays. Bacterially expressed and purified GST-MVaf1, GST-
MVcf, GST-MT (positive control), and GST (negative control) were used as bait in
pull-down assays, whereas MBP-DLC2 or MBP (control) were used as prey. Bait
proteins (200mg) were adsorbed to 50ml Glutathione-Sepharose 4B (Amersham
Biosciences) for 1 h, at 4 1C, on a rocker. Beads were washed thrice with cold
PBS and prey proteins (200 or 800mg) were incubated with bait-treated resin for
18 h at 4 1C on a rocker. Beads were washed again and bound material was
eluted from beads with 50ml SDS-PAGE sample buffer at 50 1C, using microSpin
columns (Promega, San Luis Obispo, CA, USA) at 5000 g for 5 min. Eluates
were subjected to SDS-PAGE and western blotting, and were immunodetected by
anti-myosin-Va MT (anti-MT), anti-GFP (Clontech), anti-Bcl2 (BD Biosciences,
Franklin Lakes, NJ, USA), anti-DLC/PIN (Santa Cruz Biotechnology, Santa Cruz,
CA, USA) or anti-DLC/LC-8, generated against Clamydomonas LC-8 R-4058. Pull-
down assays were also performed with cell lysates from HEK-293T expressing
different EGFP fusion proteins or EGFP alone (negative control).
RNA extraction and Northern blot analysis. Total RNA was extracted
from cell cultures of human melanoma cell lines WM35 and WM902 by using the
TRI Reagent (Sigma-Aldrich) according to the manufacturer’s instructions, and
Northern blot analysis was performed according to Nature Methods 2: 997–998
(2005), in order to assess MYO5A and DLC2 gene expression profiles at the
transcript level, while b-actin mRNA was used as the loading control.
Quantification of the specific bands from the northern blotting was measured by
the ratio of pixel intensity (relative signal) using ImageJ gel analysis software.
Melanoma model obtained by inoculation of B16 murine
melanoma cell line.
Animals. C57BL/6J mice of eight weeks were kept on a 12 h/12 h light/dark cycle,
at a normal (24 1C) animal house temperature, humidity above 55%, were fed ad
libitum and had free access to water. The experimental protocol was approved by
the Faculty of Medicine of Ribeirão Preto Bioethical Committee (process number
25000.079855/2006-96).
Selection of transduced melanoma cells and transplantation in mice. Cultures
of retrovirus packaging cells (Retropack PT67, Clontech) or HEK293T cells were
transfected with plasmids pRevTetOn/pRevTRE (bearing sequences of EGFP-
MVaf1) and pLVXTetON/pLVXTightpuro bearing EGFP, respectively. TetON
vector systems were from Clontech Laboratories, Inc., Mountain View, CA, USA.
Viruses were generated, amplified and titrated according to the manufacturer’s
manual. B16-F10 murine melanoma cells were grown to 50–70% confluence and
infected with recombinant virus. EGFP- or EGFP-MVaf1-expressing cells were
sorted after brief induction with doxycycline (1mg/ml for 24 h, half of the regular
concentration and time required for peak expression). Sorting was done using a
cell sorter flow cytometer (FACsAria from BD Biosciences, San Jose, CA).
A mixed population of green fluorescent cells was sorted and cultured for
expansion of the cells in doxycycline-free complete medium. These cells,
representing not a clone, but a mixed population of transduced cells (referred to as
‘Sorted’ EGFP-MVaf1 cells) were used for transplantation in vivo for tumorigenicity
assays (Figures 6a, b and d). Also we generated two independent clonal lineages,
C3 and G3, which were used for tumorigenicity assays to determine survival rates
(Figure 6c). C57BL/6J mice were shaved dorsally and received subcutaneous
injections of B16-F10 melanoma cells (5 105 cells in PBS), on each posterior
flank. The right flanks were injected with B16-F10 melanoma cells transduced with
EGFP-MVaf1, whereas the left flanks were injected with the same cell line
transduced with EGFP (control). The animals were divided into two groups (n¼
8/group), one of which received doxycycline in the drinking water (200mg/ml in
1% sucrose), immediately after injections and along all the study. Volumetric
measurement of tumors was performed externally by using a calliper. Animals
were monitored for a 30-day period or longer, until euthanasia. Experimental end-
points were preceded by limiting clinical signs such as consistent weight loss,
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apathy, lethargy, and impaired respiration. A limitation noted was relatively low
expression levels provided by the TetON system in comparison to plasmidial
transfections with the Qiagen SuperFect reagent.
Clonogenic assay of cells in vitro. Approximately 600 cells (WT B16-F10
cells or stably transduced B16-F10 cells) were seeded in 60-mm dishes and treated
with 2mg/ml doxycycline. Colonies were fixed with paraformaldehyde (4.0% v/v in
PBS) for 20 min, stained with crystal violet (0.2% w/v in PBS) and washed with
H2Odd. Plates were photographed and colonies were counted using the software
Image J v.1.42q.
Statistical analysis. Results are presented as the mean±S.E.M. Statisti-
cally significant difference between two means was assessed by the Student’s
t-test. Significant differences of growth parameters between two or more groups
were assessed by two-way ANOVA followed by Bonferroni post hoc test. The level
of significance was set at 1% (Po0.01). Statistical analysis of tumor growth
experiments was performed using the unpaired two-tailed Student’s t-test to
assess the significance of the mean difference. Differences between designated
groups compared with the control group were considered significant at values of
Po0.05. All analyses were performed with GraphPad Prism 5.0 (GraphPad
Software, San Diego, CA, USA).
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